- Exchange: NASDAQ GM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Amicus Therapeutics Inc
+ Add to WatchlistFOLD:US
2.5150 USD 0.0250 0.98%As of 16:30:00 ET on 06/18/2013.
Snapshot for Amicus Therapeutics Inc (FOLD)
| Open: | 2.5800 | Day's Range: | 2.5000 - 2.6500 | Volume: | 610,563 |
|---|---|---|---|---|---|
| Previous Close: | 2.5400 | 52wk Range: | 2.3000 - 6.8899 | 1-Yr Rtn: | -51.35% |
Key Statistics for FOLD
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -1.1200 |
| Est. EPS (USD) (12/2013) | -1.3960 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 125.05 |
| Shares Outstanding (M) | 49.63 |
| 30 Day Average Volume | 406,379 |
| Price/Book (mrq) | 2.3403 |
| Price/Sale (ttm) | 11.0819 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for FOLD
Company Profile & Key Executives for FOLD
Amicus Therapeutics, Inc. is a biopharmaceutical company that develops orally-administered, small molecule drugs to treat human genetic diseases. The drugs, called pharmacological chaperones, are being developed to treat Fabray, Gaucher, and Pompe disease.
| John F CrowleyChairman/CEO | William D Baird III "Chip"Chief Financial Officer |
| David J LockhartChief Scientific Officer | Bradley L CampbellChief Business Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
FOLD News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page